HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ocaratuzumab

an anti-CD20 antibody for treatment of cancer in phase I/II clinical trials (2010)

Also Known As:

AME 133; AME-133; AME-133V; AME133; LY 2469298; LY-2469298; LY2469298

Networked: 5 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Wooldridge, James E: 3 articles (01/2015 - 02/2011)
2.	Carpenter, Susan P: 2 articles (01/2015 - 03/2012)
3.	Cronier, Damien M: 2 articles (01/2015 - 03/2012)
4.	Dang, Nam H: 2 articles (01/2015 - 03/2012)
5.	Forero-Torres, Andres: 2 articles (01/2015 - 03/2012)
6.	Ganjoo, Kristen N: 2 articles (01/2015 - 03/2012)
7.	Link, Brian K: 2 articles (01/2015 - 03/2012)
8.	Pohlman, Brad L: 2 articles (01/2015 - 03/2012)
9.	Slapak, Christopher A: 2 articles (01/2015 - 03/2012)
10.	Smith, Mitchell R: 2 articles (01/2015 - 03/2012)

Related Diseases

1.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 02/01/2011 - "Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma." 01/01/2015 - "Fifty patients with previously treated follicular lymphoma (FL) and a low-affinity genotype of FcγRIIIa received ocaratuzumab 375 mg/m(2) weekly for 4 weeks. " 01/01/2015 - "Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma." 03/01/2012 - "Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma."
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/01/2014 - "Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia." 10/01/2018 - "ADCP and ADCC induction by rituximab, ofatumumab, obinutuzumab, or ocaratuzumab was measured using treatment-naïve chronic lymphocytic leukemia (CLL) target cells and either human monocyte-derived macrophages (for ADCP) or natural killer (NK) cells (for ADCC). "
3.	Chills 03/01/2012 - "AME-133v was well tolerated by patients and common related adverse events included chills and fatigue. "
4.	Fatigue 03/01/2012 - "AME-133v was well tolerated by patients and common related adverse events included chills and fatigue. "

Related Drugs and Biologics

1.	ocaratuzumab
2.	Monoclonal Antibodies
3.	Rituximab (Mabthera)
4.	obinutuzumab
5.	ofatumumab